Aims: Multiple genetic alterations, including alternative lengthening of telomeres (ALT) and NOTCH mutations, have been described in angiosarcoma. Loss of a-thalassaemia/mental retardation syndrome X-linked (ATRX) and death domain-associated protein 6 (DAXX) expression is frequently associated with the ALT phenotype. Additionally, inhibition of NOTCH signalling induces the development of malignant vascular tumours in mice, indicating a tumour suppressive role of the NOTCH pathway in the pathogenesis of angiosarcoma. The aim of this study was to evaluate the immunohistochemical expression of ATRX, DAXX and NOTCH receptors (NOTCH1 and NOTCH2) in a large cohort of angiosarcomas, and study their clinicopathological and prognostic significance. Methods and results: One hundred and forty cases of angiosarcoma were stained for ATRX, DAXX, NOTCH1 and NOTCH2. ATRX loss (<10% labelling) was seen in seven of 118 (6%) cases, and was more frequent in deep soft tissue tumours than in other body sites (P = 0.004). Angiosarcomas with ATRX loss were associated with worse event-free survival than angiosarcomas with retained ATRX expression (P = 0.003). DAXX was retained in all specimens examined. Decreased NOTCH1 expression (≤1+ intensity) was seen in 29 of 123 (24%) cases, and was associated with a cutaneous site of origin (P = 0.013) and advanced disease (P = 0.026). NOTCH2 expression was decreased in 16 of 103 (16%) cases, was associated with visceral tumours (P = 0.001), and correlated with worse disease-specific survival (P = 0.033). Conclusions: ATRX, NOTCH1 and NOTCH2 expression varies in angiosarcomas and shows significant correlations with site of origin and poor clinical outcome, thus highlighting the biological heterogeneity within this tumour type.
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Introduction
Angiosarcomas are rare malignant vascular tumours that constitute <1% of soft tissue sarcomas. 1 The current understanding of genetic events involved in the pathogenesis of angiosarcomas is limited, and the prognosis for advanced disease is poor despite treatment with available targeted therapies. 2, 3 Cancer-specific telomere elongation and maintenance can result from various mechanisms that are telomerase-dependent (such as TERT promoter mutations) or telomerase-independent, such as alternative lengthening of telomeres (ALT). 4 Inactivation of athalassaemia/mental retardation syndrome X-linked (ATRX) and/or death domain-associated protein 6 (DAXX) has been associated with the ALT phenotype in multiple tumour types, such as pancreatic neuroendocrine tumours and gliomas. 5 ATRX is a chromatin-remodelling protein, and DAXX functions as an H3.3-specific histone chaperone. 6 ATRX loss and the associated ALT phenotype have been recognised in various soft tissue sarcomas, including undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma, 7, 8 and are associated with a worse outcome. [9] [10] [11] [12] Furthermore, treatment with ATR inhibitors that selectively target the ALT cells leads to cell death in ALT-positive and ATRX-deficient osteosarcoma cell lines. 13 ATRX loss has been reported in up to 21% of angiosarcomas. 14, 15 Recently, loss of ATRX and the ALT phenotype was found to be frequent in hepatic angiosarcomas, and ATRX loss showed a strong correlation with the ALT phenotype in this series. 15 These findings suggest that angiosarcomas have biological differences by site.
Mouse models also show that inhibition of NOTCH signalling can induce hepatic vascular tumours, indicating a tumour suppressive role of the NOTCH pathway in these angiosarcomas. 16, 17 NOTCH1 loss-offunction mutations and NOTCH2 aberrations have been reported in a subset of angiosarcomas. 2, 18 NOTCH1 is expressed in normal endothelial cells, and 23% of angiosarcomas show loss of NOTCH1 labelling on immunohistochemistry. 19 Decreased NOTCH1 expression or loss of NOTCH1 expression has been shown to correlate with NOTCH1 mutation status in other malignancies, such as squamous cell carcinomas. 20, 21 Interestingly, both ATRX and NOTCH1 mutations are among the genetic alterations that have led to the recent prognostic classification of gliomas. 22 In view of the role of ALT-related proteins (ATRX and DAXX) and NOTCH receptors (NOTCH1 and NOTCH2) in the pathogenesis of malignant vascular tumours, we studied the immunohistochemical expression of these biomarkers in a large cohort of angiosarcomas, and evaluated them for clinicopathological and prognostic significance.
Materials and methods

P A T I E N T S A N D T U M O U R S A M P L E S
With Institutional Review Board approval, angiosarcoma specimens from a previously described clinically annotated tissue microarray (TMA) and additional cases with whole slide sections were used for this study. 23, 24 Patient demographics, aetiology (primary/ de novo versus secondary), tumour size, site of origin, morphology (epithelioid versus non-epithelioid) and follow-up information were recorded for all cases when available. Deep soft tissue angiosarcomas were defined by the presence of the bulk of the tumour within the somatic soft tissues (deep subcutis, fascia, or skeletal muscle) or body cavities (retroperitoneum or mediastinum) without involvement of bone, viscera, or overlying skin. 23, 25, 26 Local recurrences and/ or metastases were considered as advanced disease. Immunohistochemical stains were evaluated independently by two authors (G.P. and W.L.W.). Loss of ATRX and DAXX expression was defined as <10% nuclear labelling within the tumour cells. Tumours with absent ATRX or DAXX expression were required to have positive internal controls (normal endothelial, stromal or inflammatory cells) before being considered to be negative. NOTCH1 and NOTCH2 were assessed for intensity (0-3) and percentage of tumour cells with cytoplasmic staining (0-100%). All cases with any NOTCH1 and NOTCH2 staining showed staining in >50% of tumour cells. Loss of expression or decreased expression of NOTCH1 and NOTCH2 was defined as complete loss or staining intensity of ≤1 in the presence of a positive internal control (i.e. normal endothelial cells, perivascular smooth muscle cells, or stromal cells), whereas tumours with 2+ or 3+ staning intensity were considered to have intact expression. Specimens from primary tumours were evaluated when available, and recurrent or metastatic tumours were used when the primary tumour was not available for review.
S T A T I S T I C A L A N A L Y S I S
The chi-squared test and Fisher's exact test 27 were used as appropriate to determine whether the proportions of patients with loss of staining differed between the groups of interest. Analyses of disease-specific survival (DSS) and event-free survival (EFS) were performed in patients with primary tumours. DSS was defined as the time from diagnosis until disease-specific death or last follow-up. EFS was defined as the time from diagnosis until recurrence, metastasis, or disease-specific death, whichever occurred first, or the last follow-up. Patients without follow-up information after diagnosis were excluded from the survival analyses. The distributions of DSS and EFS were estimated with the Kaplan-Meier method. 28 The log-rank test 29 was performed to test the difference in survival between the two groups of interest, with censoring of patients lost to follow-up or dying of other causes. Regression analyses of survival data based on the Cox proportional hazard regression model 30 were conducted on DSS and EFS. A stepwise selection method with P = 0.1 for entering and P = 0.05 for staying was used to build the final multivariate model with demographic characteristics. Biomarkers were then added to the above model. A two-sided P-value of <0.05 was considered to be statistically significant. All statistical analyses were performed in SAS 9.4.
Results
P A T I E N T S A N D T U M O U R S A M P L E S
One hundred and forty cases of angiosarcoma (95 primary/de-novo and 45 secondary tumours) were evaluated in this study. These comprised cores from a clinically annotated tissue microarray (n = 115) and whole slide sections (n = 25). The mean age was 56 years (range 15-88 years). The female/male ratio was 2:1 (93 females and 47 males). Ninety-five were primary/de-novo angiosarcomas from various body sites, including cutaneous tissue (n = 23), breast tissue (n = 21), visceral tissue (n = 28), deep soft tissue (n = 17), and bone (n = 6). Forty-five secondary angiosarcomas in our cohort consisted of post-radiation angiosarcomas (n = 34), chronic lymphoedema-associated angiosarcomas (n = 7) or angiosarcomas arising secondarily in other malignancies, such as malignant peripheral nerve sheath tumour or germ cell tumour (n = 4). Cases that had viable tumours with positive internal controls were incorporated in statistical analysis, including ATRX (n = 118), DAXX (n = 106), NOTCH1 (n = 123) and NOTCH2 (n = 103) expression. Table 1 ). All cases with ATRX loss were primary/de-novo angiosarcomas (four of 14 deep soft tissue angiosarcomas, two of 20 cutaneous angiosarcomas, and one of 16 visceral angiosarcomas), whereas all post-radiation and chronic lymphoedema-associated cases retained ATRX expression (9% versus 0%, P = 0.047). ATRX loss was more common in angiosarcomas arising in deep soft tissues than in those arising in other body sites (29% versus 3%, P = 0.004) ( Table 1) . Of the seven cases with ATRX loss, five were primary tumours (four deep soft tissue angiosarcomas and one hepatic angiosarcoma), and two were metastases from primary cutaneous angiosarcomas. Tumour size, morphology and primary versus advanced disease did not show correlations with ATRX expression. DAXX was evaluated in 106 specimens, and showed retained nuclear expression in all cases examined. Table 1 ), and was associated with cutaneous site of origin (50% versus 19%, P = 0.013) and smaller size (<50 mm) (31% versus 12%, P = 0.028). Nineteen per cent of primary tumours had decreased NOTCH1 expression, as compared with 39% of advanced cases (P = 0.026). NOTCH2 expression was decreased/lost in 16 of 103 (16%) cases, with decreased or loss of NOTCH2 expression more frequent in visceral angiosarcomas than in non-visceral angiosarcomas (40% versus 10%, P = 0.003).
S U R V I V A L A N A L Y S I S
Ninety-two patients with primary tumours had available follow-up (median, 4.10 years), of which 47 (51%) had disease-specific death ( Figure 1 . Examples of angiosarcomas with a-thalassaemia/mental retardation syndrome X-linked (ATRX), NOTCH1 and NOTCH2 expression: a metastatic cutaneous angiosarcoma showing loss of nuclear ATRX expression with an adjacent example with retained ATRX expression; cardiac angiosarcomas with decreased and retained NOTCH1 expression; and cardiac angiosarcoma with decreased NOTCH2 expression, and an adjacent bladder angiosarcoma showing retained NOTCH2 expression. Lymphocytes, cardiac muscle cells and stromal cells were used as internal controls for ATRX, NOTCH1, and NOTCH2, respectively.
was associated with worse DSS [hazard ratio 2.41 (95% CI 1.08-5.39), P = 0.033] in multivariate analysis controlling for epithelioid morphology, whereas no significant correlation was seen with EFS (Figure 2) .
Discussion
In this series, loss of ATRX expression and decreased NOTCH1 and NOTCH2 expression were seen in 6%, 24% and 16% of cases, respectively whereas DAXX expression was retained in all cases examined. Angiosarcomas constitute a heterogeneous group of vascular malignancies that show genetic events and activation of different pathways based on the aetiology or site of origin. For instance, some angiosarcomas arising in the breast show KDR mutations, 31 radiation-associated angiosarcomas show MYC and FLT4 amplifications as well as mutations in the angiogenesis-related genes PTPRB and PLCG1, 3, 32, 33 whereas transforming growth factor-b signalling and PTEN expression differ between bone and soft tissue angiosarcomas. 34 In our series, ATRX loss was significantly associated with deep soft tissue angiosarcomas, whereas decreased NOTCH1 and NOTCH2 expression were more common in angiosarcomas of cutaneous and visceral origin, respectively. Our findings suggest that NOTCH pathway and ALT involvement in the pathogenesis of angiosarcomas can vary by site of origin.
ATRX loss was seen in 6% (7/118) of all angiosarcomas and in 29% (4/14) of angiosarcomas arising in deep soft tissue. Thus, ATRX loss and the related ALT phenotype play a role in a subset of deep soft tissue angiosarcomas, in addition to their association with hepatic angiosarcomas as previously described. 15 Our series included only one hepatic angiosarcoma that showed ATRX loss. In keeping with the findings of Liau et al., all secondary angiosarcomas in our cohort retained ATRX expression. ATRX loss has been described in 0-21% of angiosarcomas, 14, 15 whereas our cohort showed ATRX loss in 6% of cases. The higher percentage of ATRX-deficient cases in the study by Liau et al. might be attributable to a greater proportion of hepatic angiosarcomas in their series.
Sarcomas with the ALT phenotype and ATRX loss have been associated with poor clinical outcome. [9] [10] [11] [12] In the present series, angiosarcomas with ATRX loss had inferior EFS than those with retained ATRX expression. The loss of ATRX expression in a subset of angiosarcomas suggests a role of ALT as a telomere maintenance mechanism in these tumours.
The NOTCH pathway plays an oncogenic or tumour suppressive role in various malignancies. 35 The NOTCH pathway in mammals includes four NOTCH receptors (NOTCH1-NOTCH4). Mouse model studies have supported the role of NOTCH1 as a tumour suppressor, 16, 17 and both NOTCH1 loss-offunction mutations and NOTCH2 aberrations have been identified in human angiosarcomas. 2, 18 Rare missense NOTCH3 mutations have been described in angiosarcomas, 2 whereas genetic alterations affecting NOTCH4 have not been reported in angiosarcomas, to the best of our knowledge. In our cohort, decreased NOTCH1 expression was significantly associated with a cutaneous site of origin and advanced disease, whereas weak NOTCH2 labelling was frequently seen in visceral angiosarcomas. Moreover, decreased NOTCH2 expression correlated with worse DSS. These clinicopathological differences in NOTCH receptor expression indicate that the NOTCH pathway plays a role in a subset of angiosarcomas.
A limitation of our study is that we did not evaluate all of our cases for ALT or NOTCH mutations by sequencing. However, the ALT phenotype has a strong association with ATRX loss in most soft tissue sarcomas. Notably, in the series of Liau et al., 15 all ATRX-deficient angiosarcomas showed the ALT phenotype. As is inherent to all studies using TMAs, variable protein expression patterns can sometimes be missed, owing to tumour heterogeneity and sampling. Fortunately, evaluation of whole tissue sections in our series revealed a homogeneous pattern in the biomarkers examined. In summary, ATRX loss was seen in 6% of angiosarcomas in our series, and was more common in primary/de-novo angiosarcomas and deep soft tissue tumours. Decreased NOTCH1 expression was associated with a cutaneous site of origin and advanced disease, whereas decreased NOTCH2 expression was more common in visceral angiosarcomas. ATRX loss was associated with poor EFS, and decreased NOTCH2 expression was correlated with worse DSS. Thus, the ALT phenotype and the NOTCH pathway possibly play a role in the pathogenesis and prognosis in a subset of angiosarcomas, highlighting the biological heterogeneity of these tumours. Tumours that do harbour these alterations may be candidates for targeted therapy in the future.
